Address
Sussex Innovation Centre
Brighton, BN1 9SB
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 1273 704440
Sector
Healthcare
Industry
Biotechnology
Employees
15
First IPO Date
September 04, 2017
| Name | Title | Pay | Year Born |
| Christopher John Tovey | Chief Executive Officer & Director | 123,000 | 1965 |
| Debra Stephanie Barker | Interim CMO & Senior Independent Director | 213,000 | 1962 |
| William Guy Love | Founder, Chief Scientific Officer & Director | 250,000 | 1962 |
| Shaun Claydon | Chief Financial Officer, Company Secretary & Director | 270,000 | 1968 |
Destiny Pharma plc is a biotechnology company based in Brighton, UK, founded in 1996, specializing in the identification, progression, and market introduction of pharmaceutical solutions for infectious diseases. The company's clinical pipeline includes NTCD-M3, currently in Phase III trials to prevent recurring Clostridioides difficile infections. Its XF-73 program features XF-73 Nasal, undergoing Phase II development for the prevention of post-surgical staphylococcal infections, and XF-73 Dermal, which is in Phase I for treating bacterial skin infections resistant to antibiotics. Additionally, Destiny Pharma's preclinical efforts involve SPOR-COV, a biotherapeutic product aimed at preventing COVID-19 and other viral respiratory diseases, and XF Drugs Biofilm, targeting antibiotic-resistant biofilm and bacterial aggregate infections. The company is also investigating further applications of its XF drugs for respiratory, oral mucosa, and ocular infections. Destiny Pharma maintains strategic alliances with various organizations, including China Medical System Holdings Limited, SporeGen Limited, the University of Southampton, Aston University, the University of Sheffield, Cardiff University, and Tianjin Medical University.